实用肝脏病杂志 ›› 2024, Vol. 27 ›› Issue (4): 531-534.doi: 10.3969/j.issn.1672-5069.2024.04.010

• 非酒精性脂肪性肝病 • 上一篇    下一篇

中国临床试验注册中心注册的非酒精性脂肪性肝病临床试验特征分析*

李开楊, 赵琦, 黄敬, 唐云, 蔺晓源, 刘杰民, 杨梅   

  1. 550002 贵阳市 贵州中医药大学第二临床医学院(李开楊);贵州省人民医院内镜中心(刘杰民);第二附属医院检验科(杨梅);消化内科(赵琦,黄敬,唐云);湖南中医药大学第一附属医院医学创新实验中心(蔺晓源)
  • 收稿日期:2023-12-11 出版日期:2024-07-10 发布日期:2024-07-10
  • 通讯作者: 杨梅,E-mail:908417289@qq.com
  • 作者简介:李开楊,男,27岁,医学硕士,医师。主要研究方向:中西医结合防治消化系统疾病研究。E-mail:1592877812@qq.com
  • 基金资助:
    *国家自然科学基金资助项目(编号:82160866);贵州省科技计划项目[编号:黔科合基础-ZK(2023)一般433];贵州省卫生健康委科学技术基金资助项目(编号:gzwkj2023-208);贵州省高等学校重点实验室资助项目[编号:黔教技(2023)017号];贵州省普通高等学校青年科技人才成长项目[合同书编号:黔教合KY字(2022)263号]

Non-alcoholic fatty liver diseases: Clinical trials registered in Chinese clinical trial registry

Li Kaiyang, Zhao Qi, Huang Jing, et al   

  1. Second Clinical Medical School,Guizhou University of Traditional Chinese Medicine,Guiyang 550002,Guizhou Province,China
  • Received:2023-12-11 Online:2024-07-10 Published:2024-07-10

摘要: 目的 分析中国临床试验注册中心(ChiCTR)注册的非酒精性脂肪性肝病(NAFLD)相关临床试验的特征和研究现状。方法 检索ChiCTR数据库建库至2023年7月15日有关NAFLD的临床试验,采用Excel 2019软件对纳入临床试验的注册时间、地区及机构、经费来源、研究类型、设计方案、干预措施、研究所处阶段、随机方法、盲法、研究中心、样本量等特征进行分析。结果 纳入NAFLD相关的临床试验102项,主要以干预性研究为主,样本总量为144694例;注册地区覆盖全国17个省、直辖市,主要分布在上海、广东、浙江等地区;随机平行对照研究55项,其中有37项研究盲法填写为空白或缺失;干预措施主要包括药物干预、生活方式干预、现代诊疗技术干预和联合干预等;研究所处阶段以探索性研究/预试验、上市后药物应用/4期试验、I期临床试验为主;单中心研究88项。结论 我国NAFLD相关临床试验注册数量呈波动递增趋势,但高质量设计的临床试验不多,干预措施有限。

关键词: 非酒精性脂肪性肝病, 临床试验, 中国临床试验注册中心, 特征

Abstract: Objective This study summarized research status of clinical trials related to non-alcoholic fatty liver diseases (NAFLD) registered in Chinese Clinical Trials Registry (ChiCTR). Methods The ChiCTR database was searched for clinical trials related to NAFLD up to July 15, 2023. Excel 2019 software was used to analyze the registration time, region and institution, funding source, research type, design scheme, intervention measures, research stage, randomization or blinding method, research centers, sample size and other feature of the included clinical trials. Results A total of 102 clinical trials related to NAFLD study were included, mainly intervention studies, with a total sample of 144694 cases; the registered areas covered 17 provinces and municipalities directly under the Central government, mainly distributed in Shanghai, Guangdong, Zhejiang and other regions; the study design was mainly randomized parallel controlled studies, while there were 37 studies missing blind method or blanks; intervention measures mainly included medicine and lifestyle, modern diagnosis and treatment technology and combined interventions; the research phase mainly included exploratory research/pre-trial, post-marketing drugs/phase 4 trial and phase I clinical trial; there were 88 single-center studies, while multi-center study seldom if ever. Conclusion The numbers of NAFLD related clinical trial registrations in China is increasing, but lack of high-level, well-designed and multi-center studies.

Key words: Non-alcoholic fatty liver diseases, Clinical trials, Chinese clinical trial registry, Feature